This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Retaspimycin HCl

Infinity Pharmaceuticals, Inc.

Drug Names(s): IPI-504, MEDI561, MEDI-561, retaspimycin hydrochloride for injection

Description: IPI-504 is a proprietary agent that has demonstrated in preclinical studies to potently and selectively inhibit Heat Shock Protein 90 (Hsp90), thereby killing cancer cells. IPI-504 preferentially targets and accumulates in tumor tissues, sparing healthy tissues. In preclinical studies it has demonstrated a broad potential to treat cancer as both a single agent as well as in combination with existing anti-cancer drugs. IPI-504 is currently delivered in a water-based formulation.

Hsp90 is a therapeutic target for the treatment of cancer. Proteins are the mainstay of structural and signaling elements of all cells. Hsp90 functions to stabilize and maintain the equilibrium of proteins in the cancer cell, thereby allowing a cancer cell to survive despite an abundance of misfolded and unstable proteins.

Deal Structure: IPI-504 is Infinitys novel, proprietary agent.

Discovery Partners International and Infinity Pharmaceuticals announced in April 2006 that they entered into a definitive merger agreement to create a new public entity focused on cancer drug discovery and development. Infinity Pharmaceuticals will operate from its current headquarters in Cambridge, Massachusetts.

Upon closing of the transaction, the new company's common stock is expected to trade on the NASDAQ National Market under the name Infinity Pharmaceuticals, Inc. for which the company has reserved the symbol, INFI. DPI's current ticker symbol, DPII, will become inactive after closing.

MedImmune and Infinity Pharmaceuticals announced in August 2006 that they entered into an agreement to jointly develop and commercialize novel small molecule cancer drugs targeting Hsp90 and the Hedgehog cell-signaling pathway. IPI-504 is included in theagreement.

Under the terms of the agreement, MedImmune and Infinity will share equally...See full deal structure in Biomedtracker

Partners: AstraZeneca PLC

Retaspimycin HCl News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug